Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Ligand Fourth Quarter 2020 Earnings Webcast

Portfolio
Technologies
Licensing Opportunities

Latest News

Ligand Reports Fourth Quarter and Full Year 2020 Financial Results

Read More

Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis

Read More

Ligand’s Fourth Quarter Financial Results to be Reported February 3rd

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range